Clinically, by blocking this event, that is, the application of anti‐PD‐1 and anti‐PD‐L1 antibodies can not only facilitate the T cells’ proliferation, but also restore their cytotoxic responses against tumour cells.14, 17. Here, CD274 is linked to neoplasm.